HSP90B2P and lymphoma: These data suggest that intracellular HSP upregulation is a normal cellular response to T cell activation and that this response is dysregulated in activated T cells in lymphoma patients, which was further supported by the dysregulated expression of immune checkpoints and STAT3 in lymphoma patients.